The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot #	Exp Date	NDC
VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Suspension for Intramuscular Injection (For VFC (Vaccines for Children) or CDC Adult Vaccine)	W021510	08Oct2023	0006-4329-01 0006-4329-03
	W027250	09Jul2024	0006-4329-01 0006-4329-03
	W021512	08Oct2023	0006-4329-01 0006-4329-03
	W021637	08Oct2023	0006-4329-01 0006-4329-03
	W028846	21Nov2023	0006-4329-01 0006-4329-03

Merck has initiated a recall of VAXNEUVANCE™ Lots W021510, W021512, W021637, W027250, W028846 in the US market due to reports of breakage at the syringe flange and/or hub that could be identified when the syringe was inspected before administration, while the healthcare professional was securing the needle to the syringe, during vaccine administration or during post-administration (e.g., when activating a safety needle). This recall is to the user level and was distributed between July 2022 and July 2023.